Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration

Misa Suzuki, Norihiro Nagai, Kanako Izumi-Nagai, Hajime Shinoda, Takashi Koto, Atsuro Uchida, Hiroshi Mochimaru, Kenya Yuki, Mariko Sasaki, Kazuo Tsubota, Yoko Ozawa

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background/aims: To study the initial characteristics and response to intravitreal ranibizumab (IVR) treatment of age-related macular degeneration (AMD). Methods: We reviewed the clinical records of 141 eyes in 141 AMD patients who received monthly IVR for 3 months and thereafter pro re nata (PRN) injections for 9 months as the first treatment for AMD. Patients whose best corrected visual acuity (BCVA) worsened at month 12, and those with increased exudative fundus findings after IVR or an increased central retinal thickness of more than 100 μm at month 12, were considered to be non-responders as judged by BCVA and fundus findings, respectively. Non-responders' initial characteristics were analysed using logistic regression models. Results: 14.9% of eyes were non-responders as judged by BCVA, and 17.0% were non-responders as judged by fundus findings. Initial fibrovascular pigment epithelial detachment (PED) (OR 22.9, 95% CI 2.61 to 201) and serous PED (OR 4.12, 95% CI 1.08 to 15.8) were associated with non-response as judged by BCVA. Initial fibrovascular PED (OR 33.5, 95% CI 2.95 to 381) and type 1 choroidal neovascularization (OR 6.46, 95% CI 1.39 to 30.0) were associated with non-response, as judged by fundus findings. Conclusions: Although most AMD responded to IVR, non-responders had initial clinical characteristics that might be informative for managing their treatment.

Original languageEnglish
Pages (from-to)1186-1191
Number of pages6
JournalBritish Journal of Ophthalmology
Volume98
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Macular Degeneration
Visual Acuity
Logistic Models
Choroidal Neovascularization
Therapeutics
Injections
Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. / Suzuki, Misa; Nagai, Norihiro; Izumi-Nagai, Kanako; Shinoda, Hajime; Koto, Takashi; Uchida, Atsuro; Mochimaru, Hiroshi; Yuki, Kenya; Sasaki, Mariko; Tsubota, Kazuo; Ozawa, Yoko.

In: British Journal of Ophthalmology, Vol. 98, No. 9, 2014, p. 1186-1191.

Research output: Contribution to journalArticle

Suzuki, Misa ; Nagai, Norihiro ; Izumi-Nagai, Kanako ; Shinoda, Hajime ; Koto, Takashi ; Uchida, Atsuro ; Mochimaru, Hiroshi ; Yuki, Kenya ; Sasaki, Mariko ; Tsubota, Kazuo ; Ozawa, Yoko. / Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. In: British Journal of Ophthalmology. 2014 ; Vol. 98, No. 9. pp. 1186-1191.
@article{11dfbf1796e54c5bb8465fb74f0e2a21,
title = "Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration",
abstract = "Background/aims: To study the initial characteristics and response to intravitreal ranibizumab (IVR) treatment of age-related macular degeneration (AMD). Methods: We reviewed the clinical records of 141 eyes in 141 AMD patients who received monthly IVR for 3 months and thereafter pro re nata (PRN) injections for 9 months as the first treatment for AMD. Patients whose best corrected visual acuity (BCVA) worsened at month 12, and those with increased exudative fundus findings after IVR or an increased central retinal thickness of more than 100 μm at month 12, were considered to be non-responders as judged by BCVA and fundus findings, respectively. Non-responders' initial characteristics were analysed using logistic regression models. Results: 14.9{\%} of eyes were non-responders as judged by BCVA, and 17.0{\%} were non-responders as judged by fundus findings. Initial fibrovascular pigment epithelial detachment (PED) (OR 22.9, 95{\%} CI 2.61 to 201) and serous PED (OR 4.12, 95{\%} CI 1.08 to 15.8) were associated with non-response as judged by BCVA. Initial fibrovascular PED (OR 33.5, 95{\%} CI 2.95 to 381) and type 1 choroidal neovascularization (OR 6.46, 95{\%} CI 1.39 to 30.0) were associated with non-response, as judged by fundus findings. Conclusions: Although most AMD responded to IVR, non-responders had initial clinical characteristics that might be informative for managing their treatment.",
author = "Misa Suzuki and Norihiro Nagai and Kanako Izumi-Nagai and Hajime Shinoda and Takashi Koto and Atsuro Uchida and Hiroshi Mochimaru and Kenya Yuki and Mariko Sasaki and Kazuo Tsubota and Yoko Ozawa",
year = "2014",
doi = "10.1136/bjophthalmol-2013-304670",
language = "English",
volume = "98",
pages = "1186--1191",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration

AU - Suzuki, Misa

AU - Nagai, Norihiro

AU - Izumi-Nagai, Kanako

AU - Shinoda, Hajime

AU - Koto, Takashi

AU - Uchida, Atsuro

AU - Mochimaru, Hiroshi

AU - Yuki, Kenya

AU - Sasaki, Mariko

AU - Tsubota, Kazuo

AU - Ozawa, Yoko

PY - 2014

Y1 - 2014

N2 - Background/aims: To study the initial characteristics and response to intravitreal ranibizumab (IVR) treatment of age-related macular degeneration (AMD). Methods: We reviewed the clinical records of 141 eyes in 141 AMD patients who received monthly IVR for 3 months and thereafter pro re nata (PRN) injections for 9 months as the first treatment for AMD. Patients whose best corrected visual acuity (BCVA) worsened at month 12, and those with increased exudative fundus findings after IVR or an increased central retinal thickness of more than 100 μm at month 12, were considered to be non-responders as judged by BCVA and fundus findings, respectively. Non-responders' initial characteristics were analysed using logistic regression models. Results: 14.9% of eyes were non-responders as judged by BCVA, and 17.0% were non-responders as judged by fundus findings. Initial fibrovascular pigment epithelial detachment (PED) (OR 22.9, 95% CI 2.61 to 201) and serous PED (OR 4.12, 95% CI 1.08 to 15.8) were associated with non-response as judged by BCVA. Initial fibrovascular PED (OR 33.5, 95% CI 2.95 to 381) and type 1 choroidal neovascularization (OR 6.46, 95% CI 1.39 to 30.0) were associated with non-response, as judged by fundus findings. Conclusions: Although most AMD responded to IVR, non-responders had initial clinical characteristics that might be informative for managing their treatment.

AB - Background/aims: To study the initial characteristics and response to intravitreal ranibizumab (IVR) treatment of age-related macular degeneration (AMD). Methods: We reviewed the clinical records of 141 eyes in 141 AMD patients who received monthly IVR for 3 months and thereafter pro re nata (PRN) injections for 9 months as the first treatment for AMD. Patients whose best corrected visual acuity (BCVA) worsened at month 12, and those with increased exudative fundus findings after IVR or an increased central retinal thickness of more than 100 μm at month 12, were considered to be non-responders as judged by BCVA and fundus findings, respectively. Non-responders' initial characteristics were analysed using logistic regression models. Results: 14.9% of eyes were non-responders as judged by BCVA, and 17.0% were non-responders as judged by fundus findings. Initial fibrovascular pigment epithelial detachment (PED) (OR 22.9, 95% CI 2.61 to 201) and serous PED (OR 4.12, 95% CI 1.08 to 15.8) were associated with non-response as judged by BCVA. Initial fibrovascular PED (OR 33.5, 95% CI 2.95 to 381) and type 1 choroidal neovascularization (OR 6.46, 95% CI 1.39 to 30.0) were associated with non-response, as judged by fundus findings. Conclusions: Although most AMD responded to IVR, non-responders had initial clinical characteristics that might be informative for managing their treatment.

UR - http://www.scopus.com/inward/record.url?scp=84906937127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906937127&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2013-304670

DO - 10.1136/bjophthalmol-2013-304670

M3 - Article

C2 - 24711658

AN - SCOPUS:84906937127

VL - 98

SP - 1186

EP - 1191

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 9

ER -